Cytonet, Vesta Therapeutics Inc. deal

Vesta will manufacture Cytonet's liver cell therapies for up to two years. Cytonet's HHLivC heterologous liver cell infusion is in a Phase II/III trial to treat acute liver failure, with a Phase II/II...